Modification of Doses of Efavirenz According to Its Blood Concentration in HIV Patients

HIV Clinical Trial

Official title:

Open, Parallel and Randomised Pilot Clinical Trial to Evaluate the Utility of the Therapeutic Monitoring of Plasma Levels of Efavirenz in Hiv-Infected Patients Initiating an Antiretroviral Treatment Regimen With Sustiva

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00299091
• Other study ID #: startTDM-EFV
• Secondary ID: 2005-002493-30
• Status: Completed
• Phase: Phase 4
• First received: March 3, 2006
• Last updated: February 13, 2018
• Start date: September 2006
• Est. completion date: October 2008

Study information

• Verified date: February 2018
• Source: Germans Trias i Pujol Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a study on the utility of the modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring) in HIV-infected patients initiating treatment with Sustiva.

Description:

Currently, efavirenz is dosed systematically, without taking into account the individual characteristics of each individual patient. However, plasma concentration of efavirenz may widely vary between different subjects that receive the same dose of the drug (interindividual variability).

Therapeutic drug monitoring (TDM) signifies individualised pharmacological dosing, based on the plasma levels that each patient presents. This strategy has been broadly used in the field of the treatment of other medical conditions and is acquiring growing interest in the field of antiretroviral treatment. Thus, the use of TDM for the treatment of naïve patients with nelfinavir or with indinavir has translated into an increase in the proportion of individuals with suppressed viral load and also into a reduction in HAART-induced adverse events . However, data on the utility of the therapeutic monitoring of the levels of efavirenz in HIV-infected patients are very scant.

On the basis of the above, it might be thought that the modification of the doses of efavirenz, guided by its plasma concentration, in patients receiving this drug and whose plasma levels of efavirenz are outside the therapeutic range, might improve the tolerability of the treatment without compromising virological efficacy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: October 2008
• Est. primary completion date: October 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• HIV-1 patients.

• According to the criteria of the treating physician, the need to initiate a regimen of antiretroviral treatment that includes efavirenz (both antiretroviral-naive patients and others on treatment with protease inhibitors switching to efavirenz for salvage reasons or for simplification of the anti-retroviral therapy are included).

• Absence of opportunistic infections and/or tumours in the three months prior to inclusion.

Exclusion Criteria:

• History of allergic hypersensitivity to the investigational drug.

• History of previous failure with antiretroviral treatment with non-nucleoside reverse transcriptase inhibitors or previously documented resistance to efavirenz

• History of psychiatric comorbidity which, in the investigator's opinion, renders the use of efavirenz inadvisable.

• Active consumption of alcohol (>50 g/day) or other illegal drugs (except cannabis)

• Suspicion of unsuitable compliance with the antiretroviral treatment.

• Pregnant women or breast-feeding mothers.

Related Conditions & MeSH terms

• HIV

Intervention

Drug:
• Efavirenz capsules 200 mg and 600 mg
Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)

Locations

Country	Name	City	State
Spain	Germans Trias i Pujol Hospital	Badalona	Barcelona

Sponsors (1)

Lead Sponsor	Collaborator
Germans Trias i Pujol Hospital

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of patients who need to interrupt treatment with efavirenz due to virological failure		after 96 weeks of follow-up
Secondary	The proportion of patients who need to interrupt treatment with efavirenz due to adverse side effects		after 96 weeks of follow-up
Secondary	To determine the incidence of adverse events and the toxicity profile (haemogram, AST/ALT/FA/GGT, creatinine, urea)		during the 96 weeks of follow-up
Secondary	To evaluate the proportion of patients with plasma levels of efavirenz between 1.0 and 4.0 mg/L		during the 96 weeks of follow-up
Secondary	To evaluate the relationship between the appearance of secondary events during treatment with efavirenz and the patients' demographic and clinical characteristics, as well the plasma concentration of efavirenz		during the 96 weeks of follow-up
Secondary	To evaluate the variations in CD4 and CD8 lymphocyte count		during the 96 weeks of follow-up